TY  - JOUR
AU  - Zita, Sophia
AU  - Broussard, Lindsey
AU  - Hugh, Jeremy
AU  - Newman, Sabrina
PY  - 2023
DA  - 2023/7/20
TI  - Cyclosporine in the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: Retrospective Cohort Study
JO  - JMIR Dermatol
SP  - e41391
VL  - 6
KW  - drug reaction with eosinophilia and systemic symptoms
KW  - drug-induced hypersensitivity syndrome
KW  - drug reactions
KW  - eosinophils
KW  - cyclosporine
KW  - treatment
KW  - skin
KW  - rash
KW  - dermatology
KW  - drug reaction
KW  - adverse reaction
KW  - eosinophil
KW  - eosinophilia
KW  - Systemic Symptoms
KW  - drug-induced
KW  - drugs
KW  - cohort study
KW  - case series
KW  - pharmaceutic
KW  - pharmacology
KW  - pharmacy
AB  - Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, life-threatening reaction to a culprit drug that frequently involves end-organ damage. Corticosteroids are the first-line treatment for DRESS syndrome; however, corticosteroids may be contraindicated in certain patient populations. There are currently only 54 cases detailing the use of cyclosporine for the treatment of DRESS syndrome reported in the literature. Objective: The aim of this case series was to examine the treatment of DRESS syndrome with cyclosporine in a large patient cohort by aggregating time to symptom resolution, recurrence rate, and treatment dose and duration. Methods: This study was a retrospective cohort study. Patients diagnosed with DRESS syndrome by a board-certified dermatologist and treated at the University of Colorado Hospital from 2015 to 2019 were included. Results: Our inclusion criterion was met by 19 occurrences of DRESS syndrome. With a short course of cyclosporine, 17 of 19 patients in our cohort (89%) had resolution of symptoms (mean treatment length of 5.26 days). DRESS syndrome’s relapse after treatment with cyclosporine occurred in 3 of 19 (16%) occurrences of the cohort. Conclusions: Our study supports the use of cyclosporine in the treatment of DRESS syndrome, particularly in patients who are unable to sustain prolonged immunosuppression. Further research is necessary to compare the efficacy of cyclosporine to the current standard of care in a larger study population and investigate long-term outcomes. 
SN  - 2562-0959
UR  - https://derma.jmir.org/2023/1/e41391
UR  - https://doi.org/10.2196/41391
UR  - http://www.ncbi.nlm.nih.gov/pubmed/37632913
DO  - 10.2196/41391
ID  - info:doi/10.2196/41391
ER  -